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Abstract
Background: The 20-item Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-20)
is a self-report scale developed in order to assess the well-being of patients receiving antipsychotic
medication independent of the improvement in their psychotic symptoms. The current study
reports on the reliability and the psychometric properties of the Greek translation of the SWN-20.
Methods: A total of 100 inpatients or outpatients with schizophrenia (79 males and 21 females,
aged 42.6 ± 11.35 years old) from 3 different facilities were assessed with the Positive and Negative
Symptoms Scale (PANSS), the Calgary Depression Scale and the Simpson-Angus Scale, and
completed the SWN-20. The statistical analysis included the calculation of Pearson product
moment correlation coefficient, the Cronbach α and factor analysis with Varimax normalised
rotation.
Results: The SWN-20 had an α value equal to 0.79 and all the items were equal. The factor analysis
revealed the presence of seven factors explaining 66% of total variance. The correlation matrix
revealed a moderate relationship of the SWN-20 and its factors with the PANSS-Negative (PANSS-
N), PANSS-General Psychopathology (PANSS-G), the Simpson-Angus and the Calgary scales, and
no relationship to age, education and income class.
Discussion: The Greek translation of the SWN-20 is reliable, with psychometric properties close
to the original scale.
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Background
In the past, the standard approach to the assessment of
antipsychotic treatment was the rating of symptoms. In
this frame, the patients' perspective concerning pharma-
cological treatment was largely neglected. However during
the last couple of decades, especially after the develop-
ment of second-generation antipsychotics (SGAs),
research interest on this issue has markedly increased.
Moreover, the interest concerning the quality of life of
mental patients and their subjective sense of well-being,
particularly of patients with schizophrenia has also
increased. This increase is, at least partially, attributed to a
supposed favourable effect of SGAs [1].
Quality of life (QoL) and subjective well-being (SWB) are
different concepts with SWB being part of overall QoL.
They both constitute a conceptual extension of therapeu-
tic outcome criteria [2]. The patient satisfaction seems to
correlate strongly to the patient's willingness to be or stay
under any kind of treatment, thus determining the overall
outcome to a significant extent [3]. In this context, the
goals of treatment in schizophrenia nowadays include
patient-related factors such as subjective response and
quality of life. The patient's satisfaction with antipsychotic
therapy is influenced by a number of different and maybe
loosely related factors. These factors include medication
adverse effects, psychoeducation, lack of involvement in
decision making (concerning both the patient and his/her
family) and the existence or absence of a therapeutic alli-
ance [4,5]. However, the patient's perceptions concerning
their treatment are not strongly related to the severity of
illness or symptoms; on the contrary, there seems to be an
association between perceptions of treatment and medi-
cation adverse effects. In essence, this means that the
patient's perspectives markedly differ from these of his/
her psychiatrist [6]. If this is the case, then a relative lack
of adverse effects with newer drugs could result in higher
levels of satisfaction and subjective well-being, but this
remains to be proven [3,6,7]. The existence of both exter-
nal and inner motivations underpinning the patients' atti-
tudes towards medication and treatment in general
suggests that any intervention needs to take into account
both the disease and the person it afflicts, including his
subjective experience, in a personalised way of treatment
[8].
Methodologically, QoL and SWB are assessed with the use
of rating scales, some of them being self-report ones.
Although there are significant problems with definitions
and with the reliability and validity of these scales, they
constitute valuable tools for the assessment of the overall
course of patients. Several studies have shown that the
majority of schizophrenic patients are able to complete a
self-rating scale in a reliable way [6].
The 20-item Subjective Well-Being Under Neuroleptic
Treatment Scale (SWN-20) [9,10] is a self-report scale
developed in order to assess the well-being of patients
receiving antipsychotic medication, regardless of the
improvement in their psychotic symptoms. The current
study reports on the reliability and the psychometric
properties of the Greek translation of the SWN-20.
Methods
Study sample
The study sample included 100 in or outpatients suffering
from schizophrenia (21 females (21%) and 79 males
(79%)) aged 42.6 ± 11.35 (range 19 to 65 years old). Par-
ticipants came from three different private care facilities.
All patients gave informed consent and the protocol
received approval by the Aristotle University of Thessalo-
niki's Ethics Committee.
Clinical diagnosis
Diagnosis was made according to Diagnostic and Statisti-
cal Manual of Mental Disorders version IV Text Revision
(DSM-IV-TR) criteria on the basis of a semi-structured
interview. Patients were physically healthy with normal
clinical and laboratory findings.
Translation and back translation
Translation and back translation were made by two of the
authors; one of whom did the translation and the other
who did not know the original English text did the back
translation. The final translation was finalised by consen-
sus between them. The translated scale is shown in Figure
1.
Psychometric assessment
All patients were assessed with the Positive and Negative
Symptoms Scale (PANSS) (for the overall assessment of
the severity of psychotic symptoms), the Calgary Depres-
sion Scale (for the assessment of depression), the Simp-
son-Angus Scale (for the assessment of side effects) and
completed the SWN-20.
Statistical analysis
Descriptive statistics for all scales were calculated. Item
analysis [11] was performed, and the value of the Cron-
bach α for the SWN-20 was calculated. Principal compo-
nent analysis (without and after Varimax normalised
rotation) [12] was performed, and factor coefficients and
scores were calculated. The Pearson correlation coefficient
(R) was calculated to assess the relationship of the SWN-
20 and its factors to the other psychometric tests.
Results
The means and standard deviations for the scores for all
scales are shown in Table 1. The SWN-20 had a CronbachAnnals of General Psychiatry 2009, 8:3 http://www.annals-general-psychiatry.com/content/8/1/3
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Subjective Well-being Under Neuroleptic Treatment Scale (SWN) in Greek Figure 1
Subjective Well-being Under Neuroleptic Treatment Scale (SWN) in Greek.
ȊʌȠțİȚμİȞȚțȒ ǼȣİȟȓĮ ȣʌȩ ĮȖȦȖȒ μİ ȃİȣȡȠȜȘʌĲȚțȐ
D. Naber
ǼȜȜȘȞȚțȒ ȂİĲȐĳȡĮıȘ-ıĲȐșμȚıȘ: ȈȚĮμȠȪȜȘ țĮȚ ıȣȞ, 2008 
ȆĮȡĮțĮȜȫ ʌȡȠıȑȟĲİ: ǵȜİȢ ȠȚ ʌȡȠĲȐıİȚȢ ĮȞĮĳȑȡȠȞĲĮȚ ıĲȚȢ 7 ʌȡȠȘȖȠȪμİȞİȢ ȘμȑȡİȢ. ȆĮȡĮțĮȜȫ ıȘμİȚȫıĲİ ĲȘȞ
țĮĲȐȜȜȘȜȘ ĮʌȐȞĲȘıȘ.
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1. ȃȚȫșȦ ĮȞȓıȤȣȡȠȢ țĮȚ įİȞ ȑȤȦ ȑȜİȖȤȠ ĲȠȣ İĮȣĲȠȪ μȠȣ. {{{{{{
2. ȃȚȫșȦ ʌȠȜȪ ȐȞİĲĮ μİĲ Ƞı ȫ μĮ μȠȣ. {{{{{{
3. ȂȠȣ ĳĮȓȞİĲĮȚ İȪțȠȜȠ ĲȠ ȞĮ ıțȑĳĲȠμĮȚ. {{{{{{
4. ǻİȞ ȑȤȦ țĮμȓĮ İȜʌȓįĮ ȖȚĮ ĲȠ μȑȜȜȠȞ. {{{{{{
5. ȃȚȫșȦ ĲȠ ıȫμĮ μȠȣ ȠȚțİȓȠ. {{{{{{
6. ǼȓμĮȚ ȞĲȡȠʌĮȜȩȢ ȩĲĮȞ ȖȞȦȡȓȗȦ țĮȚȞȠȪȡȖȚȠȣȢ ĮȞșȡȫʌȠȣȢ. {{{{{{
7. ǼȓμĮȚ ȖİμȐĲȠȢ ȚįȑİȢ țĮȚ ĳĮȞĲĮıȓĮ. {{{{{{
8. ȉȠ ʌİȡȚȕȐȜȜȠȞ μȠȣ, μȠȣ ĳĮȓȞİĲĮȚ ĳȚȜȚțȩ țĮȚ ȠȚțİȓȠ. {{{{{{
9. ȃȚȫșȦ ĮįȪȞĮμȠȢ țĮȚ İȟĮıșİȞȘμȑȞȠȢ. {{{{{{
10. ȉĮ ıȣȞĮȚıșȒμĮĲĮ țĮȚ ȠȚ ĮȚıșȒıİȚȢ μȠȣ İȓȞĮȚ İʌȓʌİįĮ. ȉȓʌȠĲĮ įİȞ
ȑȤİȚ ıȘμĮıȓĮ ȖȚĮ μȑȞĮ.
{{{{{{
11. ȈțȑĳĲȠμĮȚ ĮȡȖȐ țĮȚ μİ įȣıțȠȜȓĮ. {{{{{{
12. ȉĮ ıȣȞĮȚıșȒμĮĲĮ țĮȚ Ș ıȣμʌİȡȚĳȠȡȐ μ Ƞȣ įİȞ ĮȡμȩȗȠȣȞ ıĲȚȢ
ʌİȡȚıĲȐıİȚȢ. ȈĲİȞȠȤȦȡȚȑμĮȚ ȖȚĮ μȚțȡȐ ʌȡȐȖμĮĲĮ İȞȫ ĲĮ ıȘμĮȞĲȚțȐ
μİ İʌȘȡİȐȗȠȣȞ İȜȐȤȚıĲĮ.
{{{{{{
13. ȂȠȣ İȓȞĮȚ İȪțȠȜȠ ȞĮ įȚĮĲȘȡȫ İʌĮĳȒ μİ ĲȠȣȢ ĮȞșȡȫʌȠȣȢ ȖȪȡȦ μȠȣ. {{{{{{
14. ǹȞĲȚȜĮμȕȐȞȠμĮȚ ĲȠ ʌİȡȚȕȐȜȜȠȞ μ Ƞȣ ȦȢ ĮȜȜĮȖμȑȞȠ, ʌİȡȓİȡȖȠ țĮȚ
ĮʌİȚȜȘĲȚțȩ.
{{{{{{
15. ȂʌȠȡȫ ȞĮ įȚĮȤȦȡȓıȦ ĲȠȞ İĮȣĲȩ μȠȣ Įʌȩ ĲȠȣȢ ȐȜȜȠȣȢ ĮȞșȡȫʌȠȣȢ. {{{{{{
16. ȉȠ ıȫμĮ μȠȣ, μȠȣ İȓȞĮȚ ȕȐȡȠȢ. {{{{{{
17. ȅȚ ıțȑȥİȚȢ μȠȣ ʌİĲȠȪȞ țĮȚ įİȞ țĮĲİȣșȪȞȠȞĲĮȚ. ǻȣıțȠȜİȪȠμĮȚ ȞĮ
ıțİĳĲȫ țĮșĮȡȐ.
{{{{{{
18. ȅıĮ ıȣμȕĮȓȞȠȣȞ ȖȪȡȦ μ Ƞȣ μ İ İȞįȚĮĳȑȡȠȣȞ țĮȚ ĲĮ ȕȡȓıțȦ
ıȘμĮȞĲȚțȐ.
{{{{{{
19. ȉĮ ıȣȞĮȚıșȒμĮĲĮ țĮȚ Ș ıȣμʌİȡȚĳȠȡȐ μȠȣ İȓȞĮȚ ĲĮ țĮĲȐȜȜȘȜĮ ȖȚĮ
ĲȘȞ țȐșİ ʌİȡȓıĲĮıȘ.
{{{{{{
20. ǼȓμĮȚ ȖİμȐĲȠȢ ıȚȖȠȣȡȚȐ ȩĲȚ ȩȜĮ șĮ ʌȐȞİ țĮȜȐ. {{{{{{Annals of General Psychiatry 2009, 8:3 http://www.annals-general-psychiatry.com/content/8/1/3
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α equal to 0.79 and all the items were equal. The factor
analysis (Table 2) revealed the presence of seven factors
explaining 66% of total variance.
Some items load equally to more than one factor. Item 9
equally loads to factors 1, 2, 6 and 9. Item 11 loads to fac-
tors 1 and 6, item 13 to factors 4, 6 and 7 and item 17 to
factors 2, 4 and 6.
Factor 1 includes items 1, 7, 9 and 11 and largely reflects
'mental control'. Factor 2 includes items 2, 3, 9, 16 and 17
and largely reflects a 'combined mental-physical control'.
Factor 3 includes items 4, 10 and 12 and largely reflects
'depression and loss of emotional control'. Factor 4
includes items 13, 17, 18 and 20 and reflects 'optimism'.
Factor 5 includes items 5, 15 and 19 and reflects 'self-
awareness. Factor 6 includes items 6, 9, 11, 13, and 17 and
reflects 'lack of self confidence'. Finally factor 7 includes
items 8, 9, 13 and 14 and possibly reflects a 'cognitive def-
icit' especially concerning the interpersonal domain.
The correlation matrix (Table 3) revealed a moderate-
weak relationship of the SWN-20 and its factors with the
PANSS-Positive (PANSS-P), PANSS-Negative (PANSS-N),
PANSS-General Psychopathology (PANSS-G), the Simp-
son-Angus and the Calgary scales, and no relationship to
age, education and income class.
Discussion
The Greek version of the SWN-20 is reliable with psycho-
metric properties close to the original scale. A study simi-
lar to ours that evaluated the psychometric properties of
the Italian version of the SWN showed a good perform-
ance as documented by the internal consistency, with a
Cronbach α equal to 0.85 [13], very close to that of the
Greek version (0.79). The study also reported a satisfac-
tory subjective experience in the sample's patients (SWN
mean total score 84.95, standard deviation (SD): 17.5)
[13], whereas our findings are fairly different (SWN mean
total score 66.73, SD: 14.33), probably due to the fact that
our sample consisted mainly of chronic schizophrenic
patients.
A German study applied structural equation modelling
(SEM) to the data from 360 patients with schizophrenia
in order to produce 5-item and 10-item indexes based
on the SWN scale. The 5-item index produced seems to
be a valid, time-saving tool for the assessment of the
patients' perception of well-being, and thus quality of
life [9].
Table 1: Descriptive statistics of scales scores
Scale Mean Minimum Maximum SD
SWN-20 66.73 21 95 14.33
PANSS-Positive subscale 15.12 8 32 4.76
PANSS-Negative subscale 17.82 9 37 5.13
PANSS-General Psychopathology subscale 27.21 17 45 6.04
Calgary Depression Scale 1.27 0 11 2.20
Simpson-Angus Scale 1.59 0 8 2.14
SWN-20 factor 1 12.53 3 20 3.65
SWN-20 factor 2 16.22 2 25 5.29
SWN-20 factor 3 8.01 0 10 2.53
SWN-20 factor 4 13.34 1 20 4.16
SWN-20 factor 5 9.62 0 15 3.19
SWN-20 factor 6 16.71 1 25 5.31
SWN-20 factor 7 12.80 2 20 4.49
PANSS:Positive and Negative Symptoms Scale; SD: standard deviation; SWN-20:, Subjective Well-being under Neuroleptic Treatment scale.Annals of General Psychiatry 2009, 8:3 http://www.annals-general-psychiatry.com/content/8/1/3
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Using the Quality of Life Scale (QLS) and SWN-20 scales,
a prospective naturalistic study assessed the QoL and SWB
of outpatients with schizophrenia on antipsychotic medi-
cation over a 12-month period. The analysis revealed the
presence of four different patient groups: a group with
continuously high QoL (23.2%), a group with continu-
ously moderate QoL (48.5%), a group with low QoL
(11.2%) and a group with improving QoL (19.9%) [14].
Patients and psychiatrists seem to perceive treatment and
medication side effects in a very different way. A ran-
domised double-blind multicentre trial evaluated the
Table 2: Results of the factor analysis of SWN-20
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6 Factor 7
SWN-1 0.60 0.30 0.12 0.25 -0.10 -0.05 0.18
SWN-2 0.02 0.56 -0.02 0.40 0.12 -0.02 0.19
SWN-3 -0.36 0.52 0.10 0.37 0.04 0.23 -0.22
SWN-4 -0.06 0.12 0.76 0.15 -0.02 -0.31 -0.09
SWN-5 0.00 0.27 0.36 0.22 0.60 0.06 0.12
SWN-6 -0.12 0.04 -0.02 -0.07 0.02 0.77 0.05
SWN-7 -0.79 0.16 -0.08 0.16 -0.02 -0.01 -0.01
SWN-8 0.09 -0.03 0.04 0.31 0.28 0.01 0.70
SWN-9 0.30 0.44 0.03 -0.07 -0.18 0.36 0.39
SWN-10 0.05 0.14 0.70 0.13 0.04 0.19 0.34
SWN-11 0.44 0.42 0.02 0.16 0.23 0.56 -0.06
SWN-12 0.22 -0.01 0.80 -0.12 0.14 0.15 0.02
SWN-13 -0.21 -0.16 0.28 0.55 0.12 0.41 0.37
SWN-14 0.06 0.30 0.11 -0.06 -0.05 0.10 0.76
SWN-15 -0.14 0.06 0.09 0.02 0.75 0.12 -0.14
SWN-16 -0.02 0.73 0.22 -0.13 0.28 0.10 0.19
SWN-17 0.19 0.45 0.12 0.31 0.02 0.54 0.13
SWN-18 0.01 0.04 -0.07 0.81 0.16 0.10 -0.06
SWN-19 0.14 0.06 -0.11 0.15 0.76 -0.10 0.32
SWN-20 0.02 0.22 0.22 0.62 0.04 -0.26 0.25
Proportion of total 8% 10% 10% 11% 9% 9% 9%
Total explained 66%
Values in bold underlined are factor loadings determining to which factor the specific item belongs to. SWN, Subjective Well-Being Under 
Neuroleptic Treatment Scale.Annals of General Psychiatry 2009, 8:3 http://www.annals-general-psychiatry.com/content/8/1/3
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effects of olanzapine and clozapine on subjective well-
being and clinical outcome after 26 weeks of treatment in
114 patients with schizophrenia. The results revealed only
a moderate correlation between SWN and PANSS scores,
indicating the difference of perception between patients
and psychiatrists [15]. Our results are in accordance with
these findings, showing a moderate to weak correlation
between SWN and PANSS scores.
The majority of patients with schizophrenia seem to be
satisfied with their life in general, although certain areas
are most commonly described as dissatisfactory. Hofer et
al. indicated partnership and mental health as the most
commonly noted areas. They also concluded that SWB
was negatively influenced by the depression/anxiety com-
ponent of the PANSS, extrapyramidal symptoms and a
negative attitude towards antipsychotics [16]. Side effects
of antipsychotic medication are generally considered as a
major source of subjective discomfort among patients,
leading to poor SWB [17]. A study of 161 patients suffer-
ing from schizophrenia found that patients with side
effects were less satisfied with life domains of subjective
feelings and general activities than asymptomatic
patients, and that QoL seems to be influenced by the
patient's subjective response to side effects [18]. Patients
receiving SGAs report a high perceived quality of life in
various aspects of life, although metabolic disturbances
seem to have a significant detrimental effect [19]. How-
ever, schizophrenic patients that, where switched from an
SGA to a first-generation antipsychotic (FGA) for clinical
reasons, reported no disadvantage concerning symptoms
and quality of life over a 1-year period [20]. Moreover, a
study of 1,462 patients with schizophrenia, treated either
with FGAs or SGAs showed that both quality of life and
symptom severity improved over the study period, regard-
less of the antipsychotic taken, indicating that the type of
antipsychotic does not seem to have an effect on satisfac-
tion with life [21]. Tempier et al. found that patients
receiving SGAs had lower scores in certain items about
social relationships than patients receiving FGAs, which
may be at least partially attributed to the fact that patients
receiving SGAs have greater expectations from life [22].
Research data also suggest that SWB is a major determi-
nant of adherence to treatment. In a multicentre observa-
tional study of 2960 patients suffering from
schizophrenia, SWB was assessed over a 12-month period,
with the use of SWN-20. The results showed that that the
odds for being compliant were 1.363 times higher if the
SWN-20 score increased by 20 points, indicating a strong
association between SWB and adherence to treatment
[23]. Although most of the studies are inconclusive and
their results inconsistent, SGAs seem to be superior to
FGAs in ameliorating subjective tolerability and quality of
life, thus improving adherence to treatment [24]. How-
ever, a study of 106 schizophrenic and bipolar patients
that investigated the correlation between SWB and adher-
ence to treatment, showed that although patients receiv-
ing SGAs reported a better subjective response than those
receiving FGAs, adherence to treatment did not differ
between the two groups [25]. In any case, the assessment
of the patient's subjective experience may be of use in the
evaluation of the differential effects of antipsychotics and
their dose in SWB and thus adherence to treatment [26].
Table 3: Correlation among the SWN-20 total score and factor subscales with the rest of psychometric scales and demographic 
variables
SWN Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6 Factor 7
Age 0.03 0.06 0.14 0.08 -0.01 -0.07 0.15 0.06
Education 0.07 -0.11 -0.08 -0.04 0.17 0.19 -0.13 -0.02
Income -0.09 -0.03 -0.12 0.04 -0.04 -0.11 -0.01 -0.03
PANSS-Positive subscale -0.19 -0.28 -0.17 -0.11 -0.14 -0.03 -0.28 -0.33
PANSS-Negative subscale -0.35 -0.18 -0.26 -0.16 -0.33 -0.30 -0.29 -0.15
PANSS-General Psychopathology subscale -0.36 -0.29 -0.39 -0.24 -0.28 -0.09 -0.37 -0.31
Calgary Depression Scale -0.44 -0.27 -0.37 -0.47 -0.35 -0.07 -0.24 -0.35
Simpson-Angus Scale -0.22 -0.26 -0.23 0.06 -0.12 -0.18 -0.24 -0.18
Values in bold are statistically significant at p < 0.05.
PANSS, Positive and Negative Symptoms Scale; SWN-20, 20-item Subjective Well-Being Under Neuroleptic Treatment Scale.Annals of General Psychiatry 2009, 8:3 http://www.annals-general-psychiatry.com/content/8/1/3
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Subjective well-being may also be an index of sympto-
matic remission over time and thus of predictive validity
for the course of the disease. A prospective study of 110
patients suffering from first episode schizophrenia or
related disorders investigated the impact of early improve-
ment of subjective experience and early improvement of
rater-assessed symptoms on symptomatic remission over
a 5-year period. Patients with enduring symptomatic
remission had a higher mean improvement of SWB dur-
ing early treatment, as assessed with the SWN-20, than
those without enduring symptomatic remission, indicat-
ing an association between SWB and long-term remission
[27].
In conclusion, subjective well-being is a very important,
yet neglected, concept concerning the treatment of
patients with schizophrenia receiving antipsychotics. The
subjective effects of antipsychotic medication seem to sig-
nificantly affect the patients' quality of life and willingness
to stay under treatment, thus should be considered more
thoroughly, both in clinical research and clinical practice.
The SWN-20 is a simple, easy to use, self-report scale for
the reliable assessment of the well-being of patients under
treatment with neuroleptics. The Greek translation of the
SWN-20 is reliable with psychometric properties close to
the original scale, and can be of use in implementing the
treatment of patients with schizophrenia.
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